The ASPirin in Reducing Events in the Elderly trial also demonstrated that PCSK9 pR434W is a member of lipid-lowering PCSK9 and APOB genetic variants that are carried by healthy older individuals (aged ≥ 70 years) and contribute to coronary-heart-disease-free survival [43]. Here, PCSK9 is linked to heart disorder.